 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > Experimental Models for Aging and their Potential for Novel Drug Discovery |
(Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la Salut) (Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la Salut) (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) (Department of Biological Sciences, Kent State University, Kent, OH, United States.) (Universidad Autonoma de Chile. Facultad de Ciencias de la Salud) (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) (Universitat de Barcelona. Departament de Farmacologia, Toxicologia i Química Terapèutica)
| Data: | 2018 |
| Resum: | An interesting area of scientific research is the development of potential antiaging drugs. In order to pursue this goal, it is necessary to gather the specific knowledge about the adequate preclinical models that are available to evaluate the beneficial effects of new potential drugs. This review is focused on invertebrate and vertebrate preclinical models used to evaluate the efficacy of antiaging compounds, with the objective to extend life span and health span. Research and online content related to aging, antiaging drugs, experimental aging models is reviewed. Moreover, in this review, the main experimental preclinical models of organisms that have contributed to the research in the pharmacol-ogy of lifespan extension and the understanding of the aging process are discussed. Dietary restriction (DR) constitutes a common experimental process to extend life span in all organisms. Besides, classical antiaging drugs such as resveratrol, rapamycin and metformin denominated as DR mimetics are also discussed. Likewise, the main therapeutic targets of these drugs include sirtuins, IGF-1, and mTOR, all of them being modulated by DR. Advances in molecular biology have uncovered the potential molecular pathways involved in the aging process. Due to their characteristics, invertebrate models are mainly used for drug screening. The National Institute on Aging (NIA) developed the Interventions Testing Program (ITP). At the pre-clinical level, the ITP uses Heterogeneous mouse model (HET) which is probably the most suitable rodent model to study potential drugs against aging prevention. The accelerated-senescence mouse P8 is also a mammalian rodent model for aging research. However, when evaluating the effect of drugs on a preclinical level, the evaluation must be done in non-human primates since it is the mammalian specie closest to humans. Research is needed to investigate the impact of new potential drugs for the increase of human quality of. |
| Ajuts: | Ministerio de Ciencia e Innovación SAF-2016-33307 Ministerio de Ciencia e Innovación PI-2016-01 Ministerio de Ciencia e Innovación CB06-05-0024 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014-SGR-525 Agència de Gestió d'Ajuts Universitaris i de Recerca 2014-SGR-1023 Ministerio de Ciencia e Innovación BES-2012-056083 |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article de revisió ; Article ; Versió publicada |
| Matèria: | Aging ; Resveratrol ; Sirtuins ; IGF-1 ; Mtor ; Heterogeneous mice model ; SAMP8 |
| Publicat a: | Current neuropharmacology, Vol. 16 (december 2018) , p. 1466-1483, ISSN 1875-6190 |
